Loading…
Glycogen phosphorylase inhibition improves beta cell function
Background and Purpose Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi‐s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maint...
Saved in:
Published in: | British journal of pharmacology 2018-01, Vol.175 (2), p.301-319 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Purpose
Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi‐s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maintain cellular glucose levels, which feeds into catabolism to maintain insulin secretion, and elevated glycogen degradation levels contribute to glucotoxicity. The purpose of this study was to assess whether influencing glycogen metabolism in beta cells by GPi‐s affects the function of these cells.
Experimental Approach
The effects of structurally different GPi‐s were investigated on MIN6 insulinoma cells and in a mouse model of diabetes.
Key Results
GPi treatment increased glycogen content and, consequently, the surface area of glycogen in MIN6 cells. Furthermore, GPi treatment induced insulin receptor β (InsRβ), Akt and p70S6K phosphorylation, as well as pancreatic and duodenal homeobox 1(PDX1) and insulin expression. In line with these findings, GPi‐s enhanced non‐stimulated and glucose‐stimulated insulin secretion in MIN6 cells. The InsRβ was shown to co‐localize with glycogen particles as confirmed by in silico screening, where components of InsR signalling were identified as glycogen‐bound proteins. GPi‐s also activated the pathway of insulin secretion, indicated by enhanced glycolysis, mitochondrial oxidation and calcium signalling. Finally, GPi‐s increased the size of islets of Langerhans and improved glucose‐induced insulin release in mice.
Conclusion and Implications
These data suggest that GPi‐s also target beta cells and can be repurposed as agents to preserve beta cell function or even ameliorate beta cell dysfunction in different forms of diabetes.
Linked Articles
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc |
---|---|
ISSN: | 0007-1188 1476-5381 |
DOI: | 10.1111/bph.13819 |